XM does not provide services to residents of the United States of America.
S
S

Sanofi

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Sanofi India and Dr Reddy's up on distribution partnership

BUZZ-Sanofi India and Dr Reddy's up on distribution partnership ** Shares of Sanofi India SANO.NS and Dr Reddy's Laboratories REDY.NS up 1.8% and 1.4%, respectively ** REDY, SANO partnered for distribution in India of SANO's vaccines ** SANO opened 3% higher before trimming some gains ** SANO closed 3.3% higher on Wednesday on distribution partnership with Cipla CIPL.NS ; that was stock's best day since Feb.
S

J&J can contest evidence linking its talc to cancer, US judge rules

UPDATE 3-J&J can contest evidence linking its talc to cancer, US judge rules Adds details from the ruling and background about the litigation from paragraph 13 By Dietrich Knauth NEW YORK, March 27 (Reuters) - Johnson & Johnson JNJ.N will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products.
P
S

Sanofi India and Cipla up on distribution partnership

BUZZ-Sanofi India and Cipla up on distribution partnership ** Shares of Sanofi India SANO.NS and Cipla CIPL.NS up 2.8% and 0.6% respectively ** SANO, CIPL partnered for distribution in India of six SANO products used for central nervous system-related treatments ** SANO on track for best day since Feb. 19 ** SANO top gainer on Nifty Pharma index .N
S

Indian shares set to open little changed as global rally comes to a halt

INDIA STOCKS-Indian shares set to open little changed as global rally comes to a halt BENGALURU, March 27 (Reuters) - Indian shares are likely to open little changed on Wednesday as consolidation continues near record high levels, while a global rally, fuelled by optimism around likely U.S. rate cuts this year, fizzled out. The Gift Nifty GIFc1 was trading at 22,046.50 as of 8:08 a.m.
S
S

Dyne slides after appointing new CEO

BUZZ-Dyne slides after appointing new CEO ** Shares of Dyne Therapeutics DYN.O fall ~11.5% to $25 premarket ** Co says it is appointing John Cox as its new chief executive officer ** Cox will succeed Joshua Brumm, who will serve as an advisor to Dyne after stepping down - DYNE ** Dyne says Cox has served as CEO of Biogen's rare disease spinoff Biov
B
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.